CO6862159A2 - Compuesto inhibidor de la señalización de la trayectoria notch - Google Patents

Compuesto inhibidor de la señalización de la trayectoria notch

Info

Publication number
CO6862159A2
CO6862159A2 CO14014585A CO14014585A CO6862159A2 CO 6862159 A2 CO6862159 A2 CO 6862159A2 CO 14014585 A CO14014585 A CO 14014585A CO 14014585 A CO14014585 A CO 14014585A CO 6862159 A2 CO6862159 A2 CO 6862159A2
Authority
CO
Colombia
Prior art keywords
inhibitor compound
signaling inhibitor
path signaling
notch path
notch
Prior art date
Application number
CO14014585A
Other languages
English (en)
Spanish (es)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6862159A2 publication Critical patent/CO6862159A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO14014585A 2011-07-27 2014-01-24 Compuesto inhibidor de la señalización de la trayectoria notch CO6862159A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
CO6862159A2 true CO6862159A2 (es) 2014-02-10

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14014585A CO6862159A2 (es) 2011-07-27 2014-01-24 Compuesto inhibidor de la señalización de la trayectoria notch

Country Status (36)

Country Link
US (1) US8569286B2 (enExample)
EP (1) EP2736920B1 (enExample)
JP (1) JP6027110B2 (enExample)
KR (1) KR101578309B1 (enExample)
CN (1) CN103732612B (enExample)
AP (1) AP4080A (enExample)
AR (1) AR087107A1 (enExample)
AU (1) AU2012287251B2 (enExample)
BR (1) BR112014001600B1 (enExample)
CA (1) CA2841178C (enExample)
CL (1) CL2014000175A1 (enExample)
CO (1) CO6862159A2 (enExample)
CR (1) CR20140036A (enExample)
CY (1) CY1116645T1 (enExample)
DK (1) DK2736920T3 (enExample)
DO (1) DOP2014000011A (enExample)
EA (1) EA023044B1 (enExample)
EC (1) ECSP14013179A (enExample)
ES (1) ES2544937T3 (enExample)
GT (1) GT201400012A (enExample)
HR (1) HRP20150771T1 (enExample)
HU (1) HUE027534T2 (enExample)
IL (1) IL229988A (enExample)
JO (1) JO3148B1 (enExample)
MA (1) MA35611B1 (enExample)
ME (1) ME02171B (enExample)
MX (1) MX356536B (enExample)
MY (1) MY184303A (enExample)
PE (1) PE20141061A1 (enExample)
PH (1) PH12014500215B1 (enExample)
PL (1) PL2736920T3 (enExample)
PT (1) PT2736920E (enExample)
RS (1) RS54135B1 (enExample)
SI (1) SI2736920T1 (enExample)
TW (1) TWI568730B (enExample)
WO (1) WO2013016081A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
MX380779B (es) * 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
EP3458091B1 (en) * 2016-05-20 2021-11-17 Eli Lilly and Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
JP2019526632A (ja) * 2016-08-31 2019-09-19 イーライ リリー アンド カンパニー 固形腫瘍の治療のための投薬レジメン
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
AU2018359907A1 (en) * 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
EP3790552A4 (en) * 2018-05-06 2022-06-15 Ayala Pharmaceuticals Inc. COMBINATION COMPOSITIONS WITH BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THERE
BR112021006092A2 (pt) 2018-10-02 2021-07-20 Frequency Therapeutics, Inc. composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados
MX2021012258A (es) 2019-04-08 2022-01-04 Frequency Therapeutics Inc Combinacion de chir99021 y acido valproico para tratar la perdida auditiva.
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU4707999A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CN100480248C (zh) 2003-02-04 2009-04-22 弗·哈夫曼-拉罗切有限公司 用作γ-分泌酶抑制剂的丙二酰胺衍生物
BRPI0413533A (pt) 2003-09-09 2006-10-10 Hoffmann La Roche derivados de malonamida que bloqueiam a atividade de gama-secretase
SI1673347T1 (sl) 2003-10-06 2015-10-30 F. Hoffmann - La Roche Ag Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze
WO2007110335A1 (en) 2006-03-27 2007-10-04 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma secretase inhibitors
KR101150574B1 (ko) * 2007-02-02 2012-05-30 에프. 호프만-라 로슈 아게 6-옥소-6,7-다이하이드로-5h-다이벤조[b,d]아제핀-7-일 유도체
US20090181944A1 (en) 2008-01-11 2009-07-16 John Frederick Boylan Method for cancer therapy
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
CN103732612A (zh) 2014-04-16
ES2544937T3 (es) 2015-09-07
PE20141061A1 (es) 2014-09-06
BR112014001600B1 (pt) 2022-09-13
HRP20150771T1 (hr) 2015-08-28
DOP2014000011A (es) 2014-07-31
US20130029972A1 (en) 2013-01-31
CA2841178C (en) 2016-12-20
DK2736920T3 (en) 2015-07-20
EP2736920B1 (en) 2015-07-01
ME02171B (me) 2015-10-20
EA201490161A1 (ru) 2014-04-30
PT2736920E (pt) 2015-09-16
TWI568730B (zh) 2017-02-01
US8569286B2 (en) 2013-10-29
HUE027534T2 (en) 2016-11-28
JO3148B1 (ar) 2017-09-20
JP6027110B2 (ja) 2016-11-16
BR112014001600A2 (pt) 2017-02-21
JP2014527042A (ja) 2014-10-09
CR20140036A (es) 2014-03-21
KR20140026624A (ko) 2014-03-05
PL2736920T3 (pl) 2015-11-30
PH12014500215A1 (en) 2014-03-17
KR101578309B1 (ko) 2015-12-16
EP2736920A1 (en) 2014-06-04
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
AP2014007362A0 (en) 2014-01-31
TW201315732A (zh) 2013-04-16
AR087107A1 (es) 2014-02-12
SI2736920T1 (sl) 2015-08-31
AP4080A (en) 2017-03-29
AU2012287251A1 (en) 2014-01-30
WO2013016081A1 (en) 2013-01-31
PH12014500215B1 (en) 2018-09-07
MY184303A (en) 2021-03-31
NZ618891A (en) 2015-12-24
CL2014000175A1 (es) 2014-08-22
ECSP14013179A (es) 2014-03-31
GT201400012A (es) 2014-07-16
MX356536B (es) 2018-06-01
CN103732612B (zh) 2015-09-23
MA35611B1 (fr) 2014-11-01
IL229988A (en) 2017-07-31
HK1194086A1 (en) 2014-10-10
RS54135B1 (sr) 2015-12-31
CY1116645T1 (el) 2017-03-15
AU2012287251B2 (en) 2015-05-14
MX2014001084A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
CO6900145A2 (es) Compuesto de ciclopropanoamina
AP4080A (en) Notch pathway signaling inhibitor compound
LT2751083T (lt) Kvinolono junginys
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
CR20140024A (es) Compuestos inhibidores de metaloenzimas
SMT201600308B (it) Composti di benzene arile-o eteroarile-sostituiti
HUE036259T2 (hu) Inhibitor vegyületek
DK2693881T3 (da) Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase
DK2371923T3 (da) Aflejringshæmmer
HRP20181786T1 (hr) Inhibitori aktivacije t-stanica
PL2739628T3 (pl) Nowe makrocykle jako inhibitory czynnika xia
BR112014012159A2 (pt) tetra-hidrocanabivarina fitocanabinóide
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112013023048A2 (pt) composto de guanidina
EP2710007A4 (en) Kinase inhibitors
EP2768399A4 (en) Ligation clip
CO6970602A2 (es) Inhibidores de quinasa
EP4109570C0 (en) LIGHT EMITTING DIODE
DK2678329T3 (da) Triazolopyridinforbindelser som pim-kinase-hæmmere
EP2877457A4 (en) CYSTATHIONIN-LYASE (CSE) INHIBITORS
EP2695296A4 (en) NON-FOSTER-CIRCUIT
CL2014000325A1 (es) Compuestos derivados de piranos sustituidos, implicados en la señalizacion de nematodos
BR112014012016A2 (pt) compostos
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
CO6910197A2 (es) Compuestos novedosos

Legal Events

Date Code Title Description
FG Application granted